Physician

Miho Teruya Dougherty, M.D.

According to 2025 Medicare claims, Miho Dougherty, M.D. (NPI: 1184950479) practices hematology/oncology in the Eugene-Springfield, OR market, with the plurality of this provider's patient population coming from Lane, OR. This provider's primary affiliated billing organization is ONCOLOGY ASSOCIATES OF OREGON P C (NPI: 1013989854; TIN: 930746296) and primary practice location at 97477-8802. Dougherty is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Dougherty's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 433 traditional Medicare patients, billed 57,719 HCPCS/CPT codes, and received $1,190,881 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,529 prescription claims across 290 beneficiaries totaling $2,608,987 in drug costs, led by Lenalidomide (Lenalidomide). 2022 DME data shows 17 claims. Open Payments data shows 12 records totaling $40,148. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $51,426 and ending at $1,190,881. Concurrently, Part D prescription costs have risen steadily, from $703 to $2,608,987. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	59	4,298	$51,426
2017	392	84,023	$1,165,097
2018	374	65,001	$990,590
2019	470	82,232	$1,386,893
2020	502	85,339	$1,528,744
2021	432	74,061	$1,192,698
2022	371	52,392	$987,748
2023	415	66,966	$1,244,336
2024	433	57,719	$1,190,881

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	18	37	$703
2016	25	59	$4,320
2017	112	509	$189,881
2018	112	596	$498,277
2019	154	1,106	$1,407,820
2020	204	1,341	$2,263,327
2021	202	1,390	$2,506,728
2022	203	1,002	$2,127,736
2023	222	1,193	$2,560,380
2024	290	1,529	$2,608,987

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	27	$3,200
2021	N/R	32	$2,760
2022	N/R	17	$1,022
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	118	197	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	105	180	$64
80053	Blood test, comprehensive group of blood chemicals	203	484	$10
36415	Insertion of needle into vein for collection of blood sample	231	625	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	185	529	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	37	1,001	$513,438
Verzenio	Abemaciclib	23	644	$363,276
Calquence	Acalabrutinib Maleate	23	690	$359,567
Ibrance	Palbociclib	20	560	$244,817
Nerlynx	Neratinib Maleate	11	330	$147,076

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	12	$40,148	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Miho Teruya Dougherty, M.D.?

Tedicare shows public-source Medicare data for Miho Teruya Dougherty, M.D. (NPI 1184950479), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Miho Teruya Dougherty, M.D. have ACO affiliation data?

Miho Teruya Dougherty, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Miho Teruya Dougherty, M.D.?

Miho Teruya Dougherty, M.D. is linked to ONCOLOGY ASSOCIATES OF OREGON P C (billing NPI 1013989854) in the available physician profile data.

Does Miho Teruya Dougherty, M.D. have Open Payments data?

Miho Teruya Dougherty, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.